ダントロレンによるライアノジン受容体の阻害は,構造性心疾患の患者における心室短拍の誘発を防ぐ - ランダム化比較試験
medRxiv : the preprint server for health sciences
|September 2, 2025
まとめ
構造的な心臓病の患者では,ダントロレンは心室性短拍 (VT) の誘導性を有意に低下させた. この研究は,良質な安全性プロファイルを持つ不律症の予防のためのライオノジン受容体-2 (RyR2) の標的化を支持する.
科学分野:
- 心臓病科
- 薬理学について
- 分子医学
背景:
- 20年以上にわたり,静脈性短拍 (VT) に対する新しい薬剤は開発されていない.
- 細胞内ライオノジン受容体-2 (RyR2) のカルシウム放出チャネルが漏れることは,構造的な心臓病で静脈動脈梗塞のリスクを高めます.
- ダントロレンはRyR2阻害剤であり,動物モデルでは静脈動脈症の予防に有望であることが示されています.
研究 の 目的:
- 構造的な心臓病患者の静脈動脈症の予防におけるダントロレンの有効性と安全性を評価する.
- 心臓の電気生理学的パラメータ,血液動力学,静脈動脈誘導性に対するダントロレンの効果を評価する.
主な方法:
- ランダム化され,二重盲検され,プラセボ対照の臨床試験で,心室動脈不全のためにカテーテル切除を受けた51人の患者が参加した.
- 静脈内投与ダントロレン (29人) またはプラセボ (22人)
- 静脈動脈誘導性,電気生理学的パラメータ,および血液動力学的評価 薬剤投与開始時および投与後.
主要な成果:
- ダントロレンは誘導性静脈動脈を66%減少させた (OR 0. 23,P=0. 034) が,プラセボは効果を示さなかった.
- 参加者の約半分は,開始時点で静脈線維症の誘導性であった.
- ダントロレンは伝導速度,耐火期,心拍数,心電図間隔,血圧,心機能に有意な影響を及ぼさなかった.
結論:
- ダントロレンは,高リスクの心疾患患者の静脈動脈誘導性を有意に低下させた.
- Dantroleneは,この患者集団において好ましい安全性プロファイルを示した.
- ダントロレンによるRyR2標的化は,ヒトにおける心律乱症の予防のための安全で効果的な戦略です.
関連する概念動画
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
751
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
751
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
985
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
985
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
673
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845


